ElizabethFoxMD

Pediatric Hematology & Oncology • Memphis, TN

Associate Professor, Pediatrics, Perelman School of Medicine

Join to view full profile

Dr. Fox is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fox's full profile

Already have an account?

Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105

Education & Training

National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 1996 - 1999
University of RochesterResidency, Pediatrics, 1993 - 1996
Pennsylvania State University College of MedicineClass of 1993

Certifications & Licensure

TN State Medical License 2020 - 2025
PA State Medical License 2010 - 2021
MD State Medical License 1998 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
Unknown status
Phase 3
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
Completed
Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission Start of enrollment: 2005 May 30
Completed
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Start of enrollment: 2006 Feb 20
Completed
Phase 3
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Start of enrollment: 2007 May 03
Completed
Phase 3
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Start of enrollment: 2006 Apr 01
Completed
Phase 2
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
Completed
Phase 2
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Start of enrollment: 2007 Aug 06
Active, not recruiting
Phase 3
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Nov 06
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Start of enrollment: 2007 Feb 26
Active, not recruiting
Phase 3
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 3
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Start of enrollment: 2007 Mar 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia Start of enrollment: 2007 Jan 01
Completed
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Start of enrollment: 2007 Dec 31
Completed
Phase 3
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Start of enrollment: 2008 Jan 01
Completed
Phase 2
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Jan 15
Active, not recruiting
Phase 3
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Start of enrollment: 2009 Feb 10
Completed
Phase 3
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01
Completed
Phase 2
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers Start of enrollment: 2008 Jun 02
Completed
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Start of enrollment: 2009 Mar 09
Completed
Phase 3
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment Start of enrollment: 2009 Apr 01
Completed
Phase 1
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2009 Jun 01
Completed
Phase 1
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2009 Jun 01
Terminated
Phase 1
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2009 Sep 21
Completed
Phase 1, Phase 2
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2009 Dec 21
Completed
Phase 3
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Start of enrollment: 2009 Sep 01
Completed
Phase 1
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Jun 01
Completed
Phase 1
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 2
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Start of enrollment: 2010 Sep 01
Completed
Phase 1
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
Active, not recruiting
Phase 1
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2010 Aug 09
Completed
Phase 1, Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Jan 01
Completed
Phase 1
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 1
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy Start of enrollment: 2013 Apr 01
Completed
Phase 2
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

94 citations
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Grou...
Yael P. Mosse, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris
Clinical Cancer Research. 2012-11-01
50 citations
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid
Clinical Cancer Research. 2018-12-15
60 citations
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Yael P. Mosse, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren
Clinical Cancer Research. 2019-06-01

Abstracts/Posters

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
Elizabeth Fox, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019